Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt

EU orphan designation number: EU/3/09/622   
Active ingredient: N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt
Indication: Treatment of acute myeloid leukaemia
Sponsor: Daiichi Sankyo Development Ltd
Chiltern Place, Chalfont Park, Gerrards Cross, Buckinghamshire SL9 0BG, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
25/03/2009 Orphan designation EMEA/OD/105/08 (2009)2203 of 23/03/2009
02/07/2015 Transfer of orphan designation EMA/OD/105/08/T/01 (2015)4527 of 26/06/2015